INmune Bio Receives Favorable Patentability Opinion for CORDStrom™ Platform Technology

Core Insights - INmune Bio Inc. has achieved a significant intellectual property milestone with its CORDStrom™ product, a next-generation mesenchymal stromal cell (MSC) therapy targeting inflammation and immunology [1][4] - The United States Patent and Trademark Office (USPTO) has issued a favorable written opinion on INmune Bio's international patent application, confirming the novelty and industrial applicability of all claims [2] - CORDStrom™ is designed to provide consistent therapeutic performance across various inflammatory and degenerative diseases, utilizing pooled, culture-expanded human umbilical cord-derived MSCs [3][6] Intellectual Property Developments - The favorable opinion from the USPTO confirms that all claims in the patent application possess novelty, inventive step, and industrial applicability, which are essential for patentability [2] - The patent application, once granted, will provide IP exclusivity for the CORDStrom product platform until at least 2045, with potential extensions [4] - INmune Bio plans to expedite the U.S. national application process through the Patent Prosecution Highway (PPH) program [4] Product and Clinical Development - CORDStrom™ represents an advancement in cell therapy, offering batch-to-batch consistency and tunability for multiple disease indications [4][7] - Recent Phase 2 trial data indicated that CORDStrom™ reduced pain and itch, with early signs of improved skin integrity and disease activity, marking a pivotal step for the MSC platform [5] - The CORDStrom™ platform is designed to create off-the-shelf, allogeneic MSCs that can be produced at low cost and with consistent specifications, independent of donor characteristics [6] Company Overview - INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system [8] - The company has three product platforms, including the DN-TNF platform for treating diseases like Alzheimer's and the Natural Killer Cell Priming Platform [8] - CORDStrom™ is positioned as a first systemic therapy for conditions like recessive dystrophic epidermolysis bullosa (RDEB) and can be tailored for specific indications [7]